TheraRadar
Data updated: May 26, 2026

EPIFOAM (hydrocortisone acetate)

Dermatology Approved 1979-12-19

EPIFOAM is indicated for the treatment of Dermatoses.

Source: FDA Label • Viatris
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
1
Indication
--
Phase 3 Trials
46
Years on Market

Details

Status
Prescription
First Approved
1979-12-19
Routes
TOPICAL
Dosage Forms
AEROSOL, METERED

Companies

Viatris
Active Ingredient: HYDROCORTISONE ACETATE , PRAMOXINE HYDROCHLORIDE

EPIFOAM Approval History

1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
22 FDA actions from 1979 to 2021
Apr 2021 SUPPL
Mfg · Manufacturing (CMC)
Dec 2004 SUPPL
Label · Labeling
Aug 2003 SUPPL
Label · Labeling

What EPIFOAM Treats

1 indications

EPIFOAM is approved for 1 conditions since its original approval in 1979. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Dermatoses
Source: FDA Label

EPIFOAM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

10

Same indication, different mechanism — what else might this patient receive?

HALOBETASOL PROPIONATE AND TAZAROTENE
SUN PHARMA
2025 1 indic.
CLOCORTOLONE PIVALATE
TARO
2020 1 indic.
Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to EPIFOAM

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ALA-SCALP
HYDROCORTISONE
1 shared
LEGACY PHARMA
Shared indications:
Dermatoses
ALCLOMETASONE DIPROPIONATE
ALCLOMETASONE DIPROPIONATE
1 shared
SUN PHARMA CANADA
Shared indications:
Dermatoses
AMCINONIDE
AMCINONIDE
1 shared
TARO PHARM INDS
Shared indications:
Dermatoses
View all 20 similar drugs Pro
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT02671058 CINC-2015-BA Ph 1 completed Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
NCT02689856 Hydro/Lido 143-6151-201 Ph 2 completed Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

EPIFOAM FDA Label Details

Indications & Usage

EPIFOAM is indicated for the treatment of Dermatoses.

Track EPIFOAM with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: ANDA086457 → Label: DailyMed → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.